Christopher Reardon, Dyno Therapeutics, Cambridge, MA, discusses using artificial intelligence (AI) to enhance the properties of adeno-associated virus (AAV) vectors. Whilst a vast number of changes to the capsid are possible, the advent of AI technology can refine the process to make productive alterations. The CapsidMap™ platform has enabled the optimization of AAV capsids, with the intention of using personalized AAV vectors for therapies instead of the standard AAV9 or AAV2 vectors. This interview took place at Advanced Therapies Week 2022.
Christopher Reardon is an employee of Dyno Therapeutics.